{
    "eid": "2-s2.0-85064249255",
    "title": "Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation",
    "cover-date": "2020-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pulmonary and Respiratory Medicine",
            "@code": "2740",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cardiology and Cardiovascular Medicine",
            "@code": "2705",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Cost-effectiveness analysis",
        "Non-valvular atrial fibrillation",
        "Non-Vitamin K antagonist oral anticoagulants",
        "Thailand",
        "Warfarin"
    ],
    "authors": [
        "Piyameth Dilokthornsakul",
        "Surakit Nathisuwan",
        "Rungroj Krittayaphong",
        "Aurauma Chutinet",
        "Unchalee Permsuwan"
    ],
    "citedby-count": 13,
    "ref-count": 50,
    "ref-list": [
        "Global burden of atrial fibrillation in developed and developing nations",
        "Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study",
        "Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis",
        "Thai guideline for diagnosis and treatment of atrial fibrillation",
        "Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand",
        "Optimal INR level in Thai atrial fibrillation patients who were receiving warfarin for stroke prevention in Thailand",
        "Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis",
        "Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups",
        "Cost-utility analysis of oral anticoagulants for nonvalvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand",
        "Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation",
        "Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation",
        "Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation",
        "Recovery of motor function after stroke",
        "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial",
        "Apixaban versus warfarin in patients with atrial fibrillation",
        "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation",
        "Edoxaban versus warfarin in patients with atrial fibrillation",
        "National data on stroke outcomes in Thailand",
        "Thai Registry in Acute Coronary Syndrome (TRACS) \u2014 an extension of Thai Acute Coronary Syndrome registry (TACS) group: lower in-hospital but still high mortality at one-year",
        "Hospitalized incidence and outcomes of upper gastrointestinal bleeding in Thailand",
        "Public Health Statistics 2014",
        "Rate of exchange of commercial banks",
        "Consumer price index",
        "Handling time in economic evaluation studies",
        "Handling time in economic evaluation studies",
        "Costs of lifetime treatment of acure coronary syndrome at Ramathibodi hospital",
        "Cost of acute and sub-acute care for stroke patients",
        "Cost-effectiveness analysis of celecoxib on an avoidance of gastrointestianl adverse events in pateints with osteoarthritis",
        "Unit cost of stroke rehabilitation",
        "Cost-effectiveness of PT-INR monitoring with point-of-care for dosage adjusment and adverse event in patients receiving warfarin",
        "Standard cost lists for health economic evaluation in Thailand",
        "Economic valuation of informal care in Asia: a case study of care for disabled stroke survivors in Thailand",
        "Median drug price annoucement",
        "Factors determining utility measured with the EQ-5D in patients with atrial fibrillation",
        "Long-term outcome after stroke: evaluating health-related quality of life using utility measurements",
        "Quality of life after cerebrovascular stroke: a systematic study of patients\u2019 preferences for different functional outcomes",
        "Continuing inequality: gender and social class influences on self perceived health after a heart attack",
        "Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis",
        "How patients with atrial fibrillation value different health outcomes: a standard gamble study",
        "Preference-Based EQ-5D index scores for chronic conditions in the United States",
        "Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?",
        "Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation",
        "Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis",
        "Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation",
        "Measurement of health outcomes",
        "Guidelines for health technology assessment in Thailand (second edition) \u2014 the development process",
        "Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand",
        "Thailand: WHO statistical profile",
        "The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life",
        "Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pitsanulok",
            "@id": "60022498",
            "affilname": "Naresuan University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022498",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nakhon Pathom",
            "@id": "60012718",
            "affilname": "Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012718",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60011189",
            "affilname": "Faculty of Medicine Siriraj Hospital, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011189",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60000881",
            "affilname": "Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000881",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Pfizer (Thailand) Ltd",
        "Pfizer (Thailand) Ltd."
    ]
}